North America Vet Compounding Pharmacies Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America)

North America Vet Compounding Pharmacies Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America)

The North American veterinary compounding pharmacies market has experienced robust growth in recent years. This expansion is largely driven by the increasing awareness among pet owners about animal health and the critical role of compounded medications in treating various conditions in animals. The market is expected to continue its upward trajectory, with a projected size of US$ 1.48 billion in 2024 and US$ 2.7 billion by 2031.

Key Drivers of Market Growth

Increasing Awareness and Pet Ownership

A primary factor propelling market growth is the heightened awareness of pet health among owners. Reports from the American Pet Product Association and the American Veterinary Medical Association (AVMA) indicate that nearly 84.9 million households in the U.S. own pets. This rise in pet ownership has led to a greater demand for veterinary care and compounded medications tailored to specific needs.

Cost and Availability of Generic Veterinary Drugs

The high cost and limited availability of generic veterinary drugs have also contributed to market expansion. Authorized compounding pharmacies provide more affordable and accessible options for pet owners, who often find these medications preferable to expensive branded drugs. This trend is especially notable in low-income households where the cost of animal care can be prohibitive.

Market Segmentation

CNS Agents Leading the Market

The CNS agents segment is anticipated to hold the largest market value, reaching approximately US$ 517.6 million in 2023. CNS medications are crucial for treating conditions such as attention deficit hyperactivity disorder (ADHD) in companion animals, particularly dogs, significantly contributing to market growth.

Companion Animals Dominate the Market

The companion animal segment, driven by the growing humanization of pets and increasing adoption rates, is expected to dominate the market. This segment is projected to hold around 58.7% of the market share.

Oral Formulations Preferred

Oral formulations are the most preferred method of drug administration in the veterinary sector due to their non-invasive nature, ease of administration, and patient compliance. This segment is expected to capture approximately 75.3% of the market share.

Regional Insights

U.S. Market Holds Significant Share

The U.S. is projected to maintain its dominance in the North American vet compounding pharmacies market, holding around 87.9% of the regional market share. The country's robust regulatory environment, expanding pharmaceutical sector, and increasing demand for diverse animal medications are key factors contributing to its leading position.

Canada’s Growing Market Share

Canada is expected to hold a market share of around 12.1%. The increasing popularity of pet ownership and heightened awareness of animal healthcare are driving market growth in the country. Additionally, the introduction of new products by major players is bolstering the market.

Competitive Analysis

Leading companies in the North American vet compounding pharmacies market are focusing on expanding their customer base and enhancing their market presence through the development and launch of new and improved medications. The top four companies account for approximately 35.8% of the market share.

Key Developments

In January 2021, the FDA issued a recommendation titled GFI #256, outlining the conditions under which it would not enforce laws against the bulk manufacturing of medications. This recommendation supports the development of necessary antidotes for poisons found in animal food and significant differences between compounded medications and FDA-approved drugs with the same active ingredients.

In October 2020, Virbac introduced STELFONTA, a novel injectable treatment for canine mast cell tumors, the most common form of skin cancer in dogs. This treatment demonstrated a high rate of tumor eradication and marked a significant advancement in veterinary oncology.

Key Market Players Include:

Hoye’s Pharmacy

Vertisis Custom Pharmacy

Smith Caldwell Drug Store

Sixth Avenue Medical Pharmacy

Dougherty Pharmacy

Triangle Compounding Pharmacy Inc.

Wedgewood Pharmacy

Millers Pharmacy

Chiron Compounding Pharmacy

MEDS Canadian Compounding Pharmacy

Aurora Compounding

Pace Pharmacy

Victoria Compounding Pharmacy

Pratt’s Compounding Pharmacy

People’s Choice Pharmacy

Global North America Vet Compounding Pharmacies Market Segmentation:

By Product:

CNS Agents

Anti-Infective Agents

Hormones and Substitutes

Anti-inflammatory Agents

Others

By Animal Type:

Companion Animals

Dogs

Cats

Equine

Others

Livestock Animals

By End User:

Oral

Injectable

Others

By Country:

U.S.

Canada

Please note: Delivery Timelines - 5 working days.